Look at the announcement, Xiao E is the first to report!

Haohua Technology: The fixed increase has been completed and the fundraising of 4.5 billion yuan has been received

E company news, on January 1, Haohua Technology (600378) announced that the listed company issued 181 million shares to specific objects, raising a total of 4.499 billion yuan and a net amount of 4.497 billion yuan. On December 25, 2024, the balance of the total amount of the above-mentioned raised funds after deducting the underwriting fee (including VAT) has been transferred to the special account designated by Haohua Technology for raising funds, and Tianjian Certified Public Accountants issued the "Capital Verification Report" and "Verification Report". It is reported that Haohua Technology will increase the registered capital (share capital) by 181 million yuan and increase the capital reserve by 4.315 billion yuan. At present, Haohua Technology has raised supporting funds underwriting summary and related documents have been filed and approved by the Shanghai Stock Exchange, and the company will handle the registration and custody of the new shares issued as soon as possible in accordance with relevant regulations.

Jigao Development: The company's shares may be subject to delisting risk warning

E Company News, Jigao Development (600807) announced on the evening of January 1 that on December 31, 2024, the Shenzhen Intermediate People's Court issued a first-instance judgment, ordering the company to pay 290 million yuan and liquidated damages and expenses to Fuaokang Company, totaling about 660 million yuan so far. This is a first-instance judgment, which has not yet taken effect, and the parties have the right to appeal within the prescribed time limit, and the final judgment of the case is uncertain. The company will accrue the estimated liabilities based on the first-instance judgment, which is expected to have a material adverse impact on the company's profit in 2024. According to the judgment of this lawsuit, it may lead to a situation where the company's owner's equity attributable to shareholders of the listed company is negative, such as the company's audited net assets at the end of the period in 2024 are negative, and the company's shares will be subject to delisting risk warning after the disclosure of the 2024 annual report.

BDStar: The holding subsidiary Xinhewu plans to increase its capital and expand its shares to introduce the Mutual Wealth Fund

E company news, BDStar (002151) announced on the evening of January 1 that the company's holding subsidiary Core & Things (Shanghai) Technology Co., Ltd. (hereinafter referred to as "Core & Things") intends to introduce new investors by increasing capital and shares, Zhejiang Fuzhejiang Fuchuang Equity Investment Partnership (Limited Partnership) (hereinafter referred to as "Mutual Wealth Fund") subscribed for 80 million yuan of new registered capital of 3,219,432 yuan and obtained 6.98% equity of Core & Things. The existing shareholders of Chip & Wu waived their pre-emptive right to subscribe for this capital increase. After the completion of the capital increase, the registered capital of the core and the thing will increase from 42.8989 million yuan to 46.1183 million yuan, and the company's equity ratio of the core and the thing will be changed from 63.1085% to 58.7031%, the company's control over the core and the thing will remain unchanged, and the scope of the company's consolidated statements will not change.

ST Tiansheng: The company's products are planned to be selected for centralized procurement by the National Proprietary Chinese Medicine Procurement Alliance

E company news, ST Tiansheng (002872) announced on the evening of January 1 that according to the "Announcement of the Proposed Winning Results of the National Proprietary Chinese Medicine Procurement Alliance" issued by the National Proprietary Chinese Medicine Joint Procurement Office on December 30, 2024, the company's product Danshen Granules and its wholly-owned subsidiary, Hubei Tiansheng Product Xuesaitong Injection, are planned to be selected for this centralized procurement.

Molding Technology: The chairman of the company received the decision not to prosecute and the decision to release bail pending trial

E company news, molding technology (000700) announced on the evening of January 1 that today, the company received a notice from Cao Kebo, chairman and general manager, Qian Jianfen, financial director, and Liu Hua, financial manager, who received the "decision not to prosecute" and "decision to release bail pending trial" respectively. At present, Cao Kebo, Qian Jianfen, and Liu Hua are all performing their duties normally in the company, and their subsequent normal performance will not be affected. The above events will not affect the normal operation of the company.

DEREN Electronics: The capital increase of its holding subsidiary Meta failed to arrive on time

E company news, DEREN Electronics (002055) announced on the evening of January 1 to disclose the progress of the capital increase and share expansion of its holding subsidiary Meta. Up to now, Meta's capital increase has completed the GP application, and the follow-up ODI (overseas investment filing) and other related procedures have not been completed, and the capital increase has not been paid on time. During this period, the company repeatedly urged the investor Glento Meida to complete the preparation and confirmation of the corresponding work as soon as possible, and communicated in writing on the willingness to perform and the ability to perform, but did not receive a reply and confirmation from the investor. Meta will continue to enlist the support of some customers and suppliers, and actively promote the development of new financing channels and the design of settlement plans with creditors. The Company will maintain communication with Glento Meta on the follow-up resolution of Meta's capital increase, and will consider taking relevant measures to protect the Company's legitimate rights and interests if necessary.

Aisid: Glory has recently completed the share reform

E company news, Aisid (002416) disclosed the stock price change announcement on the evening of January 1, saying that the company is the online and offline retail service provider of the Honor brand, and the authorized service provider of the Honor brand in Hong Kong, Thailand, Vietnam and other countries and regions. In 2020, the company and the team jointly invested 660 million yuan to participate in the joint acquisition of Honor. According to the information on Honor's official website, Honor Terminal Co., Ltd. has been changed to a joint stock limited company on December 28, 2024 in accordance with the law, and its company name has been changed to "Honor Terminal Co., Ltd." In addition, the company has not found any undisclosed material information that may or has had a significant impact on the trading price of the company's shares reported by the public media recently. The company, its controlling shareholders and actual controllers do not have any material matters that should be disclosed but have not been disclosed, or major matters that are in the planning stage.

ST Huicheng: It is planned to purchase 51% of the equity of Ruien Pharmaceutical for 47 million yuan, and the business will be expanded to the field of biomedicine

E company news, ST Huicheng (002168) announced on the evening of January 1 that the company intends to purchase 51% of the shares of Chongqing Ruien Pharmaceutical Co., Ltd. (hereinafter referred to as "Ruien Pharmaceutical") for 47 million yuan in cash. After the completion of the acquisition, Ruien Pharma will become a holding subsidiary of the company and be included in the company's consolidated financial statements. Ruien Pharma is mainly a high-end generic drug MAH (Drug Marketing Authorization Holder) licensee enterprise with independent intellectual property rights for drug production, sales, product introduction, product research and development. After the completion of the transaction, the company's business will be expanded to the biomedical field, helping the company expand the second curve of operating performance growth and helping the company improve its overall asset quality.

Fulongma: In 2024, the total contract amount of the winning bid for the sanitation service project is 4.607 billion yuan

E company news, Fulongma (603686) announced on the evening of January 1 that the company will pre-win the bid for 5 sanitation service projects in December 2024, with a total first-year service fee of 12.4974 million yuan (accounting for 0.40% of the company's audited operating income in 2023); The total amount of the contract is 33.9034 million yuan. Up to now, the company has won 52 bids for environmental sanitation service projects in 2024, with a total annual amount of 768 million yuan in the first year and a total contract amount of 4.607 billion yuan, which will have a positive impact on the company's operating performance in 2025 and beyond.

The vast number of special materials: plans to repurchase the company's shares with 200 million to 400 million yuan

E company news, the vast number of special materials (688186) announced on the evening of January 1 that the company intends to repurchase shares with 200 million yuan to 400 million yuan, which will be used for equity incentives and/or employee stock ownership plans, and the repurchase price of shares does not exceed 26.22 yuan per share. The source of funds for the repurchase of shares is the special loan provided by the Zhangjiagang Branch of Huaxia Bank and the company's self-raised funds, of which the special loan does not exceed 240 million yuan.

Sichuan Shuangma: The holding subsidiary obtained the certificate for the export of APIs to the European Union

E company news, Sichuan Shuangma (000935) announced on the evening of January 1 that Hubei Jianxiang, a subsidiary of the company, recently received a notice of inspection results issued by the Hubei Provincial Food and Drug Administration and a certificate for the export of APIs to the European Union. The A102 production line of Hubei Jianxiang A102 workshop (oxytocin and semaglutide) and the A092 production line (tirpatide) of A092 workshop have been inspected by the Hubei Provincial Food and Drug Administration and meet the requirements of China's drug GMP (i.e., good manufacturing practice), which is equivalent to the drug GMP requirements of the European Union, the World Health Organization and ICH Q7 (i.e., the International Council for Harmonization of Drugs for Human Use Registration Technology Good Manufacturing Practice Guidelines for APIs).

BYD: In 2024, the sales volume of new energy vehicles will be 4.2721 million units, a year-on-year increase of 41.26%.

E company news, BYD (002594) announced on the evening of January 1 that the company's sales of new energy vehicles in December 2024 were 514,800, and the cumulative sales of new energy vehicles from January to December were 4,272,100, a year-on-year increase of 41.26%.

Editor-in-charge: Peng Bo

Proofreading: Zhu Tianting